ERBB2 and breast carcinoma: We investigated a cohort of 188 women with metastatic breast cancer (MBC) treated for BrM at Sunnybrook Odette Cancer Centre from 2008 to 2018 for whom HER2 status was available in either the primary breast cancer (PBC) or metastatic site.